Multisystem inflammatory syndrome in children

The disorder has been called by various names, including:

• Multisystem inflammatory syndrome in children (MIS-C)[1]
• Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19[2]
• Paediatric inflammatory multisystem syndrome (PIMS)[7]
• Paediatric inflammatory multisystem syndrome, temporally associated with SARS-CoV-2 infection (PIMS-TS)[3][6]
• Paediatric multisystem inflammatory syndrome (PMIS)[9]
• Kawa-COVID-19[4]

Symptomatic cases of COVID-19 in children have been relatively uncommon,[24] possibly because they generally experience milder disease.[25] Early infection tends to be associated with mild or no symptoms, while the later pulmonary phase, which can be life-threatening in adults, is usually mild or absent.[26][27] While cases of children with severe symptoms are exceptional, they can occasionally require intensive care.[28][29][30] Fatalities have been rare.[27][31]

In April 2020, a small group of children with evidence of SARS-CoV-2 infection or exposure to COVID-19 were found to display clinical features corresponding to the diagnostic criteria of Kawasaki disease, sometimes accompanied by shock.[28][32] Kawasaki disease is a rare syndrome which mainly affects young children (adult onset has occasionally been reported[33]).[3][34][35] It is a form of vasculitis, where blood vessels become inflamed throughout the body, and it results in a persistent fever.[3] Recovery typically occurs spontaneously, though some children later develop mid-sized or giant coronary artery aneurysms in the heart – a potentially fatal complication.[3][36] Symptoms of toxic shock (a syndrome caused by bacterial toxins) occasionally occur – an association sometimes referred to as 'Kawasaki shock syndrome',[37] which is characterized by systolic hypotension or signs of poor perfusion.[3][38] While the exact cause of Kawasaki disease is unknown, one plausible explanation is that it may stem from an infection triggering an autoimmune and/or autoinflammatory response in children who are genetically predisposed.[39][40] No specific diagnostic test exists for Kawasaki disease, and its recognition is based on various combinations of clinical and laboratory findings (including persistent fever, widespread rashes, enlarged lymph nodes, conjunctivitis, changes to the mucous membranes, and swollen hands and feet).[3][34][41]

MIS-C / PIMS-TS is a systemic disorder involving persistent fever, extreme[6] inflammation (hyperinflammation), and organ dysfunction, which is temporally associated with exposure to COVID-19.[1][7] Onset may be delayed or contemporary with ongoing SARS-CoV-2 infection,[42] which may pass without symptoms.[6] The time the syndrome takes to appear following the initial viral infection is debated, though it may develop between the first and second week.[43] Epidemiological data suggest that recognition of the disease may typically be delayed by 2–6 weeks,[5] and usually by 3–4 weeks.[6] By the time of presention, children have often developed antibodies to SARS-CoV-2, but test negative for the virus at RT-PCR.[6]

The condition may match some or all of the diagnostic criteria for Kawasaki disease (i.e. the 'complete' or 'incomplete'/'atypical' subtypes[6][41]),[7] or for Kawasaki disease shock syndrome.[37] It tends to affect all paediatric age groups, ranging from infancy to adolescence.[5][14] It can also share clinical features with other paediatric inflammatory conditions, including toxic shock syndrome, and secondary haemophagocytic lymphohistiocytosis or macrophage activation syndrome.[7][26] Coinfections with other pathogens have been recorded.[3]

Affected children always present with persistent fever.[6] Other clinical features at presentation vary.[8] In contrast to acute COVID-19, most children have gastrointestinal symptoms, such as diarrhoea, vomiting, and intense abdominal pain (sometimes severe enough to suggest appendicitis).[6] Muscle pain and feelings of tiredness and general physical weakness are also very common.[6][9] Some Kawasaki-like symptoms that may be present (especially in children under the age of 5)[43] include mucosal changes around the mouth ("strawberry tongue", cracked lips, etc.), red eyes (conjunctivitis without pus), widespread rash (consistent with leukocytoclastic vasculitis[44]), red or swollen hands and feet, and enlarged lymph nodes.[5][8][9] Chest or neck pain may also be present.[45] Severe headache and altered mental state have been reported, along with various neurological disturbances.[5][16][46] Features of meningitis have been reported.[8][14] Some patients present with very low blood pressure and shock, and they may require urgent admission to a paediatric intensive care unit.[9]

Cardiovascular involvement is very frequent.[6][16][43] Acute heart failure is common in the form of left ventricular dysfunction,[9][47] and a left ventricular ejection fraction under 60% is frequent.[12] Shock is often of myocardial – mainly left ventricular – origin.[14] Respiratory symptoms are less common,[16] and are not usually a prominent feature.[14][8][47] When present, breathing difficulties are often linked to shock,[3] and are suggestive of heart failure.[8] Some children display features of a cytokine storm,[8] including extremely high serum interleukin-6 (IL-6) levels,[16] and need inotropic support to maintain cardiac output.[10] Coronary artery abnormalities, such as dilatation, are frequent.[9] Some children have developed coronary artery aneurysms.[8] Electrocardiographic (ECG) abnormalities are common.[9] Other cardiological features sometimes include inflammation of the heart valves (valvulitis) and of the fibrous sac surrounding the heart (pericarditis).[5][47] Echocardiographic features of myocarditis (inflammation of the heart muscle) have been recorded.[5][6]

Affected children consistently show laboratory evidence of hyperinflammation.[9] Pronounced biological markers of inflammation generally include strongly raised erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin, ferritin, and IL6.[9] Low platelet counts and impaired blood clotting (coagulopathy) are also common,[14] with increased levels of D-dimer and fibrinogen.[9] Other haematological features include raised numbers of white blood cells (leukocytosis), characterized by high numbers of neutrophils, with many immature forms, and low numbers of lymphocytes (lymphopaenia).[9] Numbers of red blood cells and platelets may be either normal or decreased.[9] Acute kidney injury and low albumin levels in the blood (hypoalbuminaemia) are common.[26] Low blood sodium levels and raised liver enzymes have been reported.[14] Accumulations of fluid in the lungs (pleural effusion), around the heart (pericardial effusion), and in the abdomen (ascites) have also been reported, consistent with generalized inflammation.[26]

Differences with respect to Kawasaki disease include frequent presentation with gastrointestinal symptoms such as vomiting, diarrhoea, and abdominal pain.[5][6] Neurological involvement also appears to be relatively frequent.[8] It often affects older children, whereas Kawasaki disease usually occurs before the age of five.[6][14] Multiorgan disease appears to be more frequent.[16] Myocarditis and cardiogenic shock shock seem to be relatively common.[16] Myocarditis may be more evident in older children and adolescents.[43] Preschool children tend to display more Kawasaki-like characteristics.[43] Features of macrophage activation syndrome appear to be more frequent than in Kawasaki disease.[17][48] Characteristic laboratory findings that are not usually encountered in Kawasaki disease include very high levels of ventricular natriuretic peptide (a marker of heart failure),[10] as well as somewhat lower platelet counts, lower absolute lymphocyte counts, and higher CRP levels.[13] Very high troponin levels (suggestive of myocardial damage) are also common.[14][26][16]

Diagnosis is by specialist clinical evaluation.[50] Diagnostic suspicion may be raised by unexplained persistent fever and clinically concerning symptoms following exposure to COVID-19.[8] Families need to seek immediate medical care, as the child's condition can deteriorate rapidly.[6] Paediatricians' first involvement is often in the emergency department.[43] Early recognition and multidisciplinary referral to paediatric specialists (in intensive care, infectious diseases, cardiology, haematology, rheumatology, etc.) is essential.[7][17][8][13] Examinations may include blood tests, chest x-ray, heart ultrasound (echocardiography), and abdominal ultrasound.[51] Clinicians worldwide have been urged to consider this condition in children who display some or all the features of Kawasaki disease or toxic shock syndrome.[18]

Due to the limited information available on this rare new diagnosis, clinical management has been largely based on expert opinion, including knowledge acquired from treating Kawasaki disease and other systemic inflammatory disorders of childhood, in addition to experience with COVID-19 in adults.[9] Treatment is tailored for each individual child, with input from the various consulting specialists.[15] Approaches vary.[57] The RCPCH initially outlined a provisional approach to clinical management, including guidance on early medical management, monitoring and some general principles of treatment;[7] for the UK, consensus has since been reached regarding a recommended pathway for clinical management (including access to registered clinical trials).[54] The National Institutes of Health provides some general considerations.[17] The American College of Rheumatology provides guidance for clinical management of MIS-C.[13][5] The American Academy of Pediatrics has also provided some interim guidance.[8] Other proposals have also been made.[9][15][45][57][58] RCPCH guidance recommends that all affected children should be treated as having suspected COVID-19.[7]

Little specific information is available regarding therapeutic effectiveness.[17] Most children who have been treated as for Kawasaki disease have recovered.[6] Supportive care is a mainstay of therapy,[17] and for mild or moderate disease it may be sufficient.[7][14] Major complications may respond well to more aggressive supportive care.[12] Cardiac and respiratory support may benefit children who present predominantly with shock.[15]

Strategies for clinical management tend to be broadly based on anti-inflammatory medications, treatment of shock, and prevention of thrombosis.[57] Most children have received immunomodulatory treatment with intravenous immunoglobulin (IVIG).[9] Other anti-inflammatory treatments have been used, including corticosteroids at various doses.[9] Good responses have been recorded for IVIG, with or without corticosteroids.[6][14][26] Cases requiring steroids due to resistance to IVIG may be more common than in Kawasaki disease.[42] In a minority of cases,[6] cytokine blockers have been used as a supplemental therapy to inhibit production of IL-6 (tocilizumab) or IL-1 (anakinra); TNF-α-inhibitors (infliximab) have also been used.[9] Inotropic or vasoactive agents are often used for children with cardiac dysfunction and hypotension.[21] Anticoagulants have been used.[21] Low-dose aspirin has been used as an antiplatelet drug.[9][8][14]

Treatment strategies are being considered to prevent serious long-term complications such as coronary artery aneurysms (the main complication of Kawasaki disease).[32] Close outpatient follow-up by a paediatric cardiology team has been recommended.[9][8]

While it has been hypothesized that the condition is related to COVID-19,[18] it has also been emphasized that the potential link "is neither established nor well understood."[3] A temporal association between SARS-CoV-2 infection and clinical presentation of the syndrome is plausible.[3] A causality assessment found that 'temporality' was among the five (out of nine) Bradford Hill criteria that supported a causal relationship between SARS-CoV-2 infection and the development of the syndrome.[3] Further characterization of the syndrome is essential to identify risk factors and help understand causality.[18] It is unclear to what extent this emerging syndrome has a similar aetiology to Kawasaki disease (a condition predating the emergence of SARS-CoV-2, which is currently thought to be triggered by a distinct viral agent).[10] Although some cases resemble toxic shock syndrome, there is no evidence that staphylococcal or streptococcal toxins are involved.[21] The role of comorbidities is unclear.[9] Improved understanding will have potential implications for clinical management.[59] Genome-wide association studies are expected to provide insights on susceptibility and potential biological mechanisms.[42]

The pathogenesis is unknown.[1][3] SARS-CoV-2 could have one of several roles; it could act as an environmental trigger for the condition either directly or indirectly (by somehow paving the way for a different trigger).[39]

As with Kawasaki disease, antibody-dependent enhancement, whereby development of antibodies could facilitate viral entry into host cells, has been proposed as a potential mechanism.[3][60] Epidemiological considerations make a post-infectious mechanism seem likely,[14][16][10][61] possibly coinciding with the development of acquired immune responses to the virus.[21] It has been suggested that the condition may be caused by the cytokine storms induced by COVID-19.[11][61] The characteristic ability of coronaviruses to block type I and type III interferon responses could help explain a delayed cytokine storm in children whose immune systems struggle to control SARS-CoV-2 viral replication, or are overwhelmed by a high initial viral load.[10] One plausible chain of events leading up to a hyperimmune response could involve early viral triggering of macrophage activation, followed by T helper cell stimulation, in turn leading to cytokine release, stimulation of macrophages, neutrophils, and monocytes, in conjunction with B cell and plasma cell activation, and antibody production.[26]

It is unknown to what extent the pathophysiology resembles that of other paediatric inflammatory syndromes that share similar clinical features.[60] Clinical overlaps with syndromes that have different causes (Kawasaki disease, toxic shock, macrophage activation syndrome, and secondary haemophagocytic lymphohistiocytosis) may be explained by immunological activation and dysregulation of similar inflammatory pathways.[62] In each of these syndromes, a cytokine storm leads to failure of multiple organs.[43] They also share with MIS-C and severe cases of COVID-19 high levels both of ferritin (released by neutrophils) and of haemophagocytosis.[43]

The frequent gastrointestinal presentation and mesenteric lymph node inflammation are in keeping with the known liking of SARS-CoV-2 to replicate in enterocytes.[10] Association of Kawasaki-like disease with COVID-19 could support the view that SARS-CoV-2 can cause systemic vasculitis by targeting endothelial tissue via angiotensin-converting enzyme 2 (ACE2), the protein which the virus uses to gain access to cells.[63] While the initial infection is known to be capable of causing acute myocardial damage, occurrence of myocarditis could also plausibly be linked to systemic hyperinflammation triggered by a disorderly post-infectious immune response.[9] It has been suggested that SARS-CoV-2 might lead to immune-mediated damage to the heart and coronary arteries via immune complexes or increased T-cell responses.[21]

Understanding the pathophysiology is a key research priority.[64] Questions regarding the underlying molecular mechanisms that lead to the disorder following exposure to SARS-CoV-2 include identification of: any genetic predisposition factors; any associations with particular viral variant/s; any molecular patterns capable of triggering the autoimmune/autoinflammatory responses.[42] Another key question is whether the molecular mechanisms that trigger autoimmune/autoinflammatory responses in children with PMIS and adults with severe COVID-19 (including the induction of high concentrations of IL-6) are similar or distinct.[42]

A potential link with Kawasaki disease is under discussion.[65] It has been noted that a leading hypothesis for the pathogenesis of Kawasaki disease also involves a hyperinflammatory response to viral infection (such as by a novel RNA virus[41][66]) in some genetically predisposed children, and that SARS-CoV-2 is now "added to the list" of implicated viral triggers.[42] Hopes have been expressed that study of the new condition may help understand the hidden mechanisms behind Kawasaki disease.[32]

Epidemiological information is limited, and clinical statistics currently derive from review of case series.[5][16][lower-alpha 1] This emerging condition is considered rare.[3] Its incidence is not known.[5][47][lower-alpha 2] Based on available reports, the fatality rate among diagnosed cases appears to have been about 1.7% (notably higher than the rate of 0.07% recorded among children with Kawasaki disease in Japan).[6] A rapid risk assessment conducted by the European Centre for Disease Prevention and Control (ECDC) concluded that the overall risk to children in the European Union (EU), European Economic Area (EEA) and the UK "is considered 'low', based on a 'very low' probability of [the disease] in children and a 'high' impact of such disease."[3]

Clusters of cases of the newly described condition have been recorded 3–4 weeks after peaks in SARS-CoV-2 viral transmission through various local communities.[14][lower-alpha 3] Such observations have been seen to support the concept that SARS-CoV-2 infection may be capable of triggering a severe form of a Kawasaki-like disease.[66] Frequent presentation without prominent respiratory symptoms in children who do not appear to have ongoing SARS-CoV-2 infection but who have already developed antibodies suggests that the disease may be driven by a delayed, post-infectious mechanism.[14]

The median age of onset appears to be at least 7 years (compared with 2 years for Kawasaki disease, which primarily affects children under the age of 5).[16] Male children seem to be more frequently affected (broadly in line with Kawasaki disease, where the male to female ratio is about 1.5 to 1).[16] Many affected children appear not to have underlying health conditions, such as asthma or autoimmune disorders, and there have been relatively few reports of known congenital heart disease or preexisting cardiovascular disease.[6][9] Over half (52%) the children with available information had no recorded underlying health condition, including being overweight or obese (among those who did have some comorbidity, 51% were either overweight or obese).[6]

Regarding ethnicity, reports from France and the UK raised the possibility that children of Afro-Caribbean descent may be at greater risk, plausibly due to a genetic predisposition.[42] In the US (as of mid-July), the majority of cases were classified as Hispanic/Latino (38%) or non-Hispanic Black (33%) people.[72] Based on reports confined to Europe and the US, the condition seems to affect more children of African, Afro-Caribbean, and Hispanic descent, whereas Kawasaki disease affects more of East Asian and Pacific Islander ancestry.[13][65] The role of socioeconomic and other environmental factors in such discrepancies is unclear.[39]

As regards geographical distribution, there has been uncertainty as to whether the initial reports of cases in Europe and North America reflected a true pattern, or whether the condition had gone unrecognized elsewhere.[3][18] In Japan and other Southeast and East Asian countries where Kawasaki disease is usually much more prevalent than in Europe, no case of Kawasaki-like disease linked to COVID-19 had been reported during the first wave of transmission.[3][10][66][73][lower-alpha 4] Reports of confirmed or suspected cases have since emerged in many different countries around the world.[21][lower-alpha 5]

None of the three main provisional case-definitions of the emerging entity is diagnostically specific.[65] Concerns have been raised regarding the potential for missed or delayed diagnosis of Kawasaki disease due to heightened diagnostic suspicion for the new entity.[56] Misclassification of cases of Kawasaki disease and of other inflammatory and infectious diseases of childhood whose case definitions overlap with MIS-C could skew understanding of the new entity, such as the frequency of coronary artery aneurysms.[93][94] Another concern is that clinically less severe cases of the new entity may be missed, and that the actual spectrum of disease severity could be broader,[21][95] especially given the reliance on early observations of severe disease for provisional case definition.[96] Some statistical modeling has been used to explore possible subdivision of cases satisfying the CDC's case definition into three distinct subgroups based on underlying clinical similarities: Class 1, characterized by pronounced multiorgan involvement, with little overlap with Kawasaki disease or acute COVID-19; Class 2, more predominantly characterized by respiratory symptoms typical of acute COVID-19; Class 3, a clinically less severe grouping, where rashes and mucosal symptoms are prevalent, with less multiorgan involvement, and generally greater overlap with Kawasaki disease.[97][49] A suggestion[96] that research into the biology of the disease might benefit from considering cases of Kawasaki disease and of the provisionally defined entity in conjunction is debated.[97]

Cases of Kawasaki disease with concurrent SARS-CoV-2 infection have been recorded among children in Europe and in the United States since 7 April 2020, when a report was published by the American Academy of Pediatrics regarding a case of 'classic' Kawasaki disease in a six-month old girl who tested positive for COVID-19 in California.[3][99] In this case, COVID-19 did not appear to have significant clinical implications.[59][99]

On 25 April, concerns were initially raised in the United Kingdom regarding a cluster of children of various ages presenting with a multisystem inflammatory state who required intensive care, and who all displayed "overlapping features of toxic shock syndrome and atypical Kawasaki disease with blood parameters consistent with severe COVID-19 in children."[32][100] Details of the eight cases which helped trigger this alert (not all with confirmed exposure to COVID-19) were later reported in The Lancet, where the authors summarized the clinical picture as "a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome."[59][101] Accounts of analogous cases – including some that appeared less clinically severe – were also being informally shared among clinicians around Europe.[32] The EU's Early Warning and Response System flagged suspected cases in Austria, Germany and Portugal that had tested positive for SARS-CoV-2.[3] In Bergamo, at the heart of the COVID-19 epidemic in Lombardy, a cluster of 20 cases of Kawasaki disease appeared to be roughly equivalent to the number commonly recorded there over the course of three years.[59] In France, the government reported on 29 April that around 15 children were in hospital in Paris with symptoms of Kawasaki disease,[59][102] an observation which prompted the organization of national surveillance programme for recent cases of Kawasaki-like disease.[68]

On 1 May, the RCPCH published a preliminary case definition based on review of the characteristics of the cases identified in the UK, accompanied by some clinical guidance.[7][32] Two weeks later, on 15 May, two further preliminary case definitions were published separately by the WHO[18] and by the CDC,[1] while the ECDC released a 'rapid risk assessment' of the condition on behalf of the European Union.[3] In the following weeks, further clinical guidance was released by other medical organizations, including the NIH,[17] the American College of Rheumatology,[19] and the American Academy of Pediatrics.[20] On 4 May, the New York City Department of Health and Mental Hygiene issued an alert to identify children with the condition in New York City hospitals,[3] where 15 such cases were already being treated.[103] On 9 May, the governor of New York, Andrew Cuomo announced a collaboration with the CDC to help develop national criteria for identifying and responding to the newly identified childhood disease.[104]

By 12 May, some 230 suspected cases had been reported across the EU and EEA, and in the UK[3] (in the following days, sources were reporting up to 100 in the UK,[105] over 135 in France,[106] 20 in the Netherlands,[107] 10 in Switzerland[108] and 10 in Germany[109]). In the United States, more than 200 cases were suspected by mid-May,[110] including some 145 in New York;[111][112] 186 confirmed cases were eventually diagnosed between 15 March and 20 May in 26 US states.[113][114] As of 11 May 2020, five fatalities were reported (1 in France, 1 in the UK, 3 in the US).[3] In peer-reviewed medical journals, case series and related studies of the new condition were rapidly reported from countries including the UK;[115][116] Italy;[69] Spain;[117][118][119] France and Switzerland;[120] France;[4][121][122] and across the US,[113][123] including New York.[67][124][125] The emerging observations suggested somewhat greater variety in the severity of symptoms than was originally thought.[17] The proposal of a new clinical entity during a pandemic also prompted scientific discussion about its possible distinction from Kawasaki disease, and the potential role of COVID-19.[32][52][59][65][66][73][94][96]

By 15 July, 342 confirmed MIS-C cases (including 6 deaths) had been recorded in the US across 36 states plus Washington DC.[72][126] Most (71%) of the children were Hispanic/Latino or non-Hispanic Black people, and the CDC underlined the need to learn the reasons for such a preponderance.[72][127] By 29 July, a total of 570 cases and 10 deaths had been reported across 40 states, Washington DC, and New York City.[49]

Until late May, no confirmed case had been documented outside the EU/EEA/UK and USA.[3] No suspicious case had been observed in East Asia or Southeast Asia (or in Australia or New Zealand).[73][128][129] The absence of documented cases in China and other Asian countries that had already experienced a COVID-19 epidemic led to conjectures regarding the possibility of a significant evolution of the virus, or variations in susceptibility in different populations.[26] On 2 June, news emerged of a first case of MIS-C diagnosed in Peru.[130][131] In Brazil, cases of MIS-C have been reported in São Paulo,[132] and in the context of a prospective study in Pará;[133] more children with severe late manifestations of COVID-19 were being admitted to paediatric intensive care units in the region.[133] In Chile, 42 confirmed cases of MIS-C had been recorded nationally by June 28, including 27 in the capital, Santiago.[134] In Russia, 13 children had been treated (5 with intensive care) by mid-June for a multisystem inflammatory syndrome at the Morozov Children's Hospital in Moscow, including a 2-year-old girl with the COVID-19 infection who died on 23 May following an initial diagnosis of suspected Kawasaki disease.[78] In Iran, a case report (first submitted in May) described severe MIS-C in a 5-year-old girl who had presented with shock and was initially diagnosed with Kawasaki disease,[85] and further cases of the new syndrome have been recorded.[86] In India, a case of suspected MIS-C was reported in late May regarding a child who had presented in a COVID-19 hotspot in Kerala.[80] An editorial commentary urged clinicians to have a high level of diagnostic suspicion and follow WHO and CDC definitions to facilitate timely identification and treatment of cases.[135]

During July, suspected cases were being flagged and reported in Mumbai,[136] in Delhi,[137] Chennai,[79] and elsewhere.[138] In Pakistan,[139] at least 24 children were said to have Kawasaki-like symptoms in Lahore,[140] where 8 cases fulfilling WHO criteria were prospectively identified by 30 June.[81] In Kazakhstan, 14 cases were confirmed by 20 August (among 2,357 children known to have been infected).[82] Cases have been recorded in Israel,[88] including one of a child who presented with severe central nervous system involvement and complement deficiency.[89] In Turkey, four children with a Kawasaki-like disease probably associated with COVID-19 are reported to have been admitted to the children's hospital of Hacettepe University in Ankara between 13 April and 11 July.[84] In Algeria, a first case was recorded in June.[90] In Egypt, on 10 July the authorities denied rumours of the existence of cases of Kawasaki-like disease in the country.[141] In South Africa, the first 23 affected children were treated in Cape Town – the initial epicentre of the national COVID-19 epidemic – between 4 June and 24 July.[91] In Ecuador, the Ministry of Health announced on 19 July the presence of 46 probable cases.[142] In Costa Rica, a national public health organization announced towards the end of August that three children had been diagnosed with MIS-C.[143] Cases of MIS-C had also been recorded in many other Latin American countries, including Argentina, Bolivia, Colombia, Cuba, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Uruguay, and Venezuela, as well as in Puerto Rico.[22] News of a first confirmed case of PIMS-TS in Australia emerged (from Victoria) on 4 September, along with news of other suspected cases under review.[144] In South Korea, news of two confirmed cases broke on 5 October[83] (and the existence of a case dating back to the end of April was reported in November[75]).

A similar condition began to be recognized in some adults.[98][23][145] In June, an adult case of a Kawasaki-like multisystem inflammatory syndrome following SARS-CoV-2 infection was described in a 54-year-old woman from Israel with no history of autoimmune disease, who experienced uveitis in both eyes.[146] (A further suspected adult case was covered in the Israeli national press.)[147] A case involving a 36-year-old Hispanic American woman with clinical features otherwise consistent with MIS-C was reported from New York.[148] A diagnosis consistent with PMIS was also reported in a UK-born, 21-year-old man of Somali origin.[149] A case report published in The Lancet regarding a 45-year-old Hispanic man who presented in New York with features strongly resembling MIS-C called for awareness of "a potential MIS-C-like condition in adults."[150] Further reports of multisystem inflammatory syndrome linked to COVID-19 exposure emerged in adults.[145][151][152][153][154] In October, the CDC reported on the condition and named it 'multisystem inflammatory syndrome in adults' (MIS-A).[23] Questions have been raised regarding possible relationships between MIS-C and certain severe manifestations of COVID-19 in adults.[98]

• Fact sheet for parents released by New York City's Health Department
• Information for parents provided by the Children's Hospital Los Angeles
• Information for paediatric health care providers in the U.S.A. (from the CDC)